Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has been given an average recommendation of “Buy” by the seven ...

Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at a public ...

Tarsus Pharmaceuticals (TARS) announced the commencement of an underwritten public offering of $100M of shares of its common stock. All shares ...

U.S. Customs and Border Protection (CBP) has claimed an object that people from Quinlan say fell from the sky on Tuesday ...

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) reported over $180 million in net product sales for 2024, exceeding expectations. The company expanded its sales force from 100 to 150 representatives ...

The Dakota Cougars defeated the Anchor Bay Tars 52-47 on Wednesday, March 5 to advance to the Division 1 district ...

Tarsus Pharmaceuticals sees growth with Xdemvy's $180M sales in 2024. Read this article to know what makes TARS stock a BUY for growth investors.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...